The US Food and Drug Administration (FDA) on Wednesday finalized guidance explaining its recently created program intended to spur the development of new antibiotic and antifungal drugs intended for ...
Merck, GlaxoSmithKline, BIO and Pew Charitable Trusts weighed in on recent draft guidance on the establishment of a limited population pathway for antibacterial and antifungal drugs (LPAD pathway).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results